Dublin (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, will announce first quarter 2012 earnings on Thursday April 26, 2012. Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT Live conference call for investors: Angus Russell, Chief Executive Officer and Graham Hetherington, ...
Dublin (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, today announced that it has signed an agreement to acquire substantially all the assets of Pervasis Therapeutics. Shire will provide Pervasis with an upfront payment, plus potential post-closing milestone payments that are dependent on Shire's achievement of certain clinical ...
Philadelphia, Pennsylvania (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, today announced top-line results of the PREVENT2 trial, a phase 3 investigational study of once-daily SPD476, MMX(R) mesalamine in patients with a history of diverticulitis.[1] The study, conducted in 10 countries worldwide including the United States, did not meet the primary endpoint in reducing the rate of ...
Dublin (ots/PRNewswire) - ? Shire plc , the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, Inc., for an upfront payment of $100 million, payable in cash at closing, plus potential post-closing milestone payments of up to $225 million, depending upon the achievement of certain clinical development, ...
Nyon, Switzerland (ots/PRNewswire) - Shire plc , the global specialty biopharmaceutical company, today announced it has received approval through the European Decentralised Procedure for an oral powder formulation of FOSRENOL (lanthanum carbonate). FOSRENOL is a non-calcium, non-resin phosphate binder indicated as a phosphate binding agent for use in the control of ...
Philadelphia and Basingstoke, England, November 6 (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney disease (CKD) patients not on dialysis.(1) FOSRENOL is a non-calcium phosphate binder, indicated to treat ...
Basingstoke, England, November 5 (ots/PRNewswire) - - For global distribution excluding the US and Canada New data presented today at the 40th annual American Society of Nephrology (ASN) meeting and scientific exposition in San Francisco, CA, USA, show that epoetin delta - the only erythropoiesis-stimulating agent (ESA) produced in a human cell line - has ...
Philadelphia (ots/PRNewswire) - At the U.S. Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee meeting today, the majority of members voted to recommend the use of phosphate binders, including Shire Pharmaceuticals' non-calcium FOSRENOL(R) (lanthanum carbonate), to treat ...
Basingstoke, England and San Diego, California, November 20 (ots/PRNewswire) - - Further Data Support the Contribution of FOSRENOL(R) (Lanthanum Carbonate) to the Overall Renal Health of the ESRD Patient While Reducing Mean Phosphate Levels to Within Guideline Targets New data presented on Friday 17th ...
Basingstoke, England (ots/PRNewswire) - Shire today announced the start of a new Phase IIIb clinical trial to evaluate two new dosing schedules of DYNEPO(R) (epoetin delta), the first commercial erythropoiesis-stimulating agent produced in a human cell line. DYNEPO is used in the treatment of anaemia in patients with chronic kidney disease (CKD[i]). Anaemia becomes ...
Basingstoke, England (ots/PRNewswire) - - Not for Distribution in the United States The first anti-anaemia treatment produced in a human cell line, DYNEPO(R) (epoetin delta), can effectively control anaemia in patients with chronic kidney disease (CKD[x]) according to two Phase III studies presented for the first time today.(1),(2) Patients with kidney ...
Basingstoke, England (ots/PRNewswire) - - New Data Show FOSRENOL Is an Effective Monotherapy - Leading to Improved Phosphate Reduction in Dialysis Patients Previously Receiving Alternative Phosphate Binder Therapies New data show calcium-free FOSRENOL (lanthanum carbonate) further reduces phosphate levels in dialysis patients previously receiving other ...
Basingstoke, England (ots/PRNewswire) - - First Human Cell Line-Derived Erythropoietin Research Reported BASINGSTOKE, England, June 16 /PRNewswire/ -- - Abstract Numbers: 562 and 576 Effective treatment of anaemia in patients suffering from chronic kidney disease (CKD)(x) is possible with the first erythropoietin product produced in a human cell ...
St Louis, Missouri (ots/PRNewswire) - Shire Pharmaceuticals Group plc (NASDAQ: SHPGY, LSE: SHP.L, TSE: SHQ CN) announced that long-term treatment with FOSRENOL(R) (lanthanum carbonate) for up to five years, shows no deterioration in bone health according to new data presented today for the first time at the ...